Cancel
About Martin Akerman
Martin Akerman is the co-founder and CTO who contributed to the development of Spinraza, the first FDA-approved RNA therapeutic for Spinal Muscular Atrophy.
Known information
Martin Akerman, holding the title of co-founder and CTO, has a distinguished background in bioinformatics, having earned his PhD from the Technion, Israel Institute of Technology. His postdoctoral training was conducted under Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he played a significant role in the development of Spinraza. This groundbreaking drug is the first FDA-approved RNA therapeutic designed to treat Spinal Muscular Atrophy. Akerman’s research primarily focused on RNA splicing and its potential to enhance the functionality of the human genome and to activate disease mechanisms.
About Envisagenics
Envisagenics is a biotechnology company that specializes in developing RNA therapeutics using its AI-driven platform, SpliceCore, which identifies and validates drug targets with a high experimental validation rate.
Report inaccurate information
